| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Rivaroxaban |
| Brand | Xarelto® |
| Indication | Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement. |
| Assessment Process | |
| Rapid review commissioned | 20/11/2017 |
| Rapid review completed | 21/11/2017 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
A full pharmacoeconomic evaluation is not required as rivaroxaban 10mg is reimbursable under the Community Drug Schemes.